<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988362</url>
  </required_header>
  <id_info>
    <org_study_id>HL068</org_study_id>
    <nct_id>NCT02988362</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)</brief_title>
  <official_title>An Open-label, Randomized, Cross-over Study to Evaluate Pharmacokinetics and the Safety of HL068 16/10mg Compared to Candesartan 16mg and Amlodipine 10mg Co-administered in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HanAll BioPharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HanAll BioPharma Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetics of HL068 (Candesartan
      16 mg and Amlodipine 10mg) with coadministration of the two separate drugs in healthy male
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t 1/2β</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Candesartan 16mg and Amlodipine 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 16mg and Amlodipine 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL068</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL068(combination of Candesartan 16 mg and Amlodipine 10 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL068 16/10mg</intervention_name>
    <description>Candesartan 16mg and Amlodipine 10mg</description>
    <arm_group_label>HL068</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan 16mg and Amlodipine 10mg</intervention_name>
    <arm_group_label>Candesartan 16mg and Amlodipine 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteer in the age between 19 and 55 years old.

          -  Body mass index (BMI) in the range of 18.5 to 27.0 kg/m2

          -  Understand the requirements of the study and voluntarily consent to participate in the
             study.

        Exclusion Criteria:

          -  Previous history or present of clinically significant digestive , cardiovascular,
             respiratory, psychiatric, endocrine, hepatobiliary, renal disease.

          -  History of gastrointestinal disease or gastrointestinal surgery to affect drug
             absorption.

          -  Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase
             deficiency or glucose-galactose malabsorption.

          -  Subjects whose clinical laboratory test values are outside the accepted normal range.
             Especially, ASTor ALT &gt;1.5 times of the Upper Normal Limit or total bilirubin &gt; 1.5
             times of the Upper Normal Limit

          -  Positive test results for Hepatitis B antibodies, Hepatitis C virus antibody, and
             Syphilis regain test

          -  Participation in any clinical investigation within 3 months prior to study drug
             administration

          -  Subjects with whole blood donation within 60 days or component blood donation within
             30days or blood transfusion within 30days prior to the first dosing.

          -  SBP ≥ 140 mmHg or&lt; 115 mmHg, DBP ≥ 90 mmHg or &lt; 70 mmHg

          -  Caffeine &gt; 400mg/day

          -  Alcohol &gt; 30g/day

          -  Cigarette &gt; 10 cigarettes/day.

          -  Subjects who are judged unsuitable by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Ran Yoon, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL CLINICAL TRIAL CENTER</affiliation>
  </overall_official>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

